HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
CD22
CD22 molecule
Chromosome 19 · 19q13.12
NCBI Gene: 933Ensembl: ENSG00000012124.18HGNC: HGNC:1643UniProt: P20273
100PubMed Papers
20Diseases
11Drugs
0Pathogenic Variants
CLINICAL
FDA Approved Target
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
early endosomerecycling endosomeextracellular exosomeprotein bindingacute lymphoblastic leukemiahairy cell leukemianeoplasmsystemic lupus erythematosus
✦AI Summary

CD22 is the most highly expressed siglec on B cells that plays crucial roles in B-cell biology including differentiation, antigen presentation, and bone marrow trafficking 1. Mechanistically, CD22 functions as an inhibitory coreceptor that binds α2,6-linked sialic acid residues on surface molecules such as CD45, IgM, and CD22 itself in cis configuration, and can also engage ligands on other cells as a trans-acting adhesion molecule 2. CD22 suppresses B-cell receptor signaling through its immunoreceptor tyrosine-based inhibitory motif, which becomes phosphorylated by the Src kinase LYN, recruiting protein tyrosine phosphatase 1/PTPN6 to negatively regulate BCR signaling and inhibit calcium mobilization 3. Sufficiently strong negative signaling can induce B-cell apoptosis 4. Beyond B cells, CD22 is upregulated on aged microglia where it negatively regulates homeostatic phagocytosis; CD22 blockade restores microglial clearance of myelin debris and protein aggregates, improving cognitive function in aged mice 5. CD22 has emerged as a therapeutic target: dual and trispecific CAR-T cells targeting CD22 alongside CD19/CD20 show enhanced efficacy against B-cell malignancies and overcome antigen escape 678. However, CD22 blockade context-dependently exacerbates neuroinflammation in neuromyelitis optica spectrum disorder through enhanced microglial activity 9.

Sources cited
1
CD22 is the most highly expressed siglec on B cells involved in B-cell differentiation, antigen presentation, and bone marrow trafficking
PMID: 34330755
2
CD22 inhibits BCR signaling through LYN-mediated phosphorylation of its ITIM domain, recruiting SHP-1/PTPN6 phosphatase
PMID: 8627166
3
CD22 binds α2,6-linked sialic acid residues on CD45, IgM, and itself in cis configuration, and acts as a trans-acting adhesion molecule
PMID: 20172905
4
Strong CD22-mediated negative signaling can induce B-cell apoptosis
PMID: 20516366
5
CD22 is upregulated on aged microglia and negatively regulates homeostatic phagocytosis; CD22 blockade restores clearance of myelin debris and improves cognitive function
PMID: 30944478
6
CRISPR-engineered dual CD19/CD22-targeting CAR-T cells achieved 83.3% complete remission rate in relapsed/refractory ALL with manageable safety
PMID: 33627493
7
Trispecific CAR-T cells targeting CD19, CD20, and CD22 overcome antigen loss-mediated relapse better than monoCAR-T cells
PMID: 33762438
8
CD19/CD22/CD3 trispecific antibody demonstrates enhanced antitumor efficacy and overcomes immune escape compared to bispecific antibodies
PMID: 35981465
9
CD22 blockade exacerbates neuroinflammation and CNS lesion formation in neuromyelitis optica spectrum disorder through enhanced microglial activity
PMID: 39616380
Disease Associationsⓘ20
acute lymphoblastic leukemiaOpen Targets
0.59Moderate
hairy cell leukemiaOpen Targets
0.50Moderate
neoplasmOpen Targets
0.49Moderate
systemic lupus erythematosusOpen Targets
0.41Moderate
B-cell acute lymphoblastic leukemiaOpen Targets
0.40Moderate
lymphomaOpen Targets
0.36Weak
leukemiaOpen Targets
0.11Weak
non-Hodgkins lymphomaOpen Targets
0.11Weak
diffuse large B-cell lymphomaOpen Targets
0.10Weak
chronic lymphocytic leukemiaOpen Targets
0.10Weak
asthmaOpen Targets
0.09Suggestive
combined immunodeficiency with skin granulomasOpen Targets
0.09Suggestive
neoplasm of mature B-cellsOpen Targets
0.09Suggestive
common variable immunodeficiencyOpen Targets
0.09Suggestive
Hodgkins lymphomaOpen Targets
0.09Suggestive
BENTA diseaseOpen Targets
0.09Suggestive
agammaglobulinemia 8, autosomal dominantOpen Targets
0.08Suggestive
immunodeficiency 18Open Targets
0.08Suggestive
classic Hodgkin lymphomaOpen Targets
0.08Suggestive
immunodeficiency 73c with defective neutrophil chemotaxis and hypogammaglobulinemiaOpen Targets
0.08Suggestive
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Drug Targets11
BECTUMOMABPhase III
CD22 other
lymphoma
BL22Phase II
CD22 binding agent
EPRATUZUMABPhase III
CD22 inhibitor
EPRATUZUMAB-CYS-TESIRINEPhase I/II
B-cell receptor CD22 binding agent
INOTUZUMABPhase III
CD22 binding agent
acute lymphoblastic leukemia
INOTUZUMAB OZOGAMICINApproved
CD22 binding agent
acute lymphoblastic leukemia
MONO-DGA-RFB4Phase I
CD22 binding agent
lymphoma
MOXETUMOMAB PASUDOTOXApproved
Elongation factor 2 inhibitor
PINATUZUMAB VEDOTINPhase II
CD22 binding agent
diffuse large B-cell lymphoma
YTTRIUM Y 90 EPRATUZUMABPhase I/II
CD22 binding agent
non-Hodgkins lymphoma
YTTRIUM Y 90 EPRATUZUMAB TETRAXETANPhase II
CD22 inhibitor
neoplasm of mature B-cells
Related Genes
CD40LGProtein interaction98%CD81Protein interaction98%PTPRCProtein interaction98%SYKProtein interaction98%FCGR3AProtein interaction96%CD79BProtein interaction96%
Tissue Expression6 tissues
Ovary
100%
Bone Marrow
14%
Brain
4%
Lung
3%
Liver
1%
Heart
1%
Gene Interaction Network
Click a node to explore
CD22CD40LGCD81PTPRCSYKFCGR3ACD79B
PROTEIN STRUCTURE
Preparing viewer…
PDB5VKJ · 2.12 Å · X-ray
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
0.64LoF Tolerant
pLIⓘ
0.00Tolerant
Observed/Expected LoF0.50 [0.40–0.64]
RankingsWhere CD22 stands among ~20K protein-coding genes
  • #4,769of 20,598
    Most Researched100 · top quartile
  • #600of 1,025
    FDA-Approved Drug Targets2
  • #4,566of 17,882
    Most Constrained (LOEUF)0.64
Genes detectedCD22
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
PMID: 33627493
Clin Cancer Res · 2021
1.00
2
CD22 blockade restores homeostatic microglial phagocytosis in ageing brains.
PMID: 30944478
Nature · 2019
0.90
3
CD22 blockade exacerbates neuroinflammation in Neuromyelitis optica spectrum disorder.
PMID: 39616380
J Neuroinflammation · 2024
0.80
4
Trispecific CD19-CD20-CD22-targeting duoCAR-T cells eliminate antigen-heterogeneous B cell tumors in preclinical models.
PMID: 33762438
Sci Transl Med · 2021
0.70
5
CD22 blockade modulates microglia activity to suppress neuroinflammation following intracerebral hemorrhage.
PMID: 37696483
Pharmacol Res · 2023
0.60